Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
25.91
-0.09 (-0.35%)
At close: Nov 8, 2024, 4:00 PM
26.49
+0.58 (2.24%)
After-hours: Nov 8, 2024, 4:23 PM EST

Company Description

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves’ disease and thyroid eye disease.

It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes.

Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.

The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Septerna, Inc.
Septerna logo
Country United States
Founded 2022
IPO Date Oct 25, 2024
Industry Biotechnology
Sector Healthcare
Employees 68
CEO Jeffrey Finer

Contact Details

Address:
250 East Grand Avenue
South San Francisco, California 94080
United States
Phone 650 338 3533
Website septerna.com

Stock Details

Ticker Symbol SEPN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001984086
Employer ID 84-3891440
SIC Code 2834

Key Executives

Name Position
Jeffrey Finer, M.D., Ph.D. Chief Executive Officer, President and Director
Liz Bhatt, M.S., M.B.A. Chief Operating Officer
Jae B. Kim, M.D. Chief Medical Officer
Samira Shaikhly Chief People Officer
Uwe Klein, Ph.D. Senior Vice President, Biological Sciences
Daniel Long, D.Phil. Senior Vice President, Drug Discovery
Jeffrey Tong, Ph.D. Chairman and Director
Abraham Bassan, M.S. Director
Alan Ezekowitz, M.D., D.Phil. Director
Bernard Coulie, M.D., Ph.D., M.B.A. Director

Latest SEC Filings

Date Type Title
Nov 4, 2024 SC 13D General statement of acquisition of beneficial ownership
Nov 4, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 1, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 28, 2024 8-K Current Report
Oct 25, 2024 S-8 Securities to be offered to employees in employee benefit plans
Oct 25, 2024 424B4 Prospectus
Oct 24, 2024 EFFECT Notice of Effectiveness
Oct 24, 2024 S-1MEF Registration adding securities to prior Form S-1 registration
Oct 24, 2024 CERT Certification by an exchange approving securities for listing
Oct 24, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933